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Purpose: The aim of this study was to analyze the oncologic outcomes and the risk factors for recurrence after a tumor-spe-
cific mesorectal excision (TSME) of resectable rectal cancer in a single institution. 
Methods: A total of 782 patients who underwent a TSME for resectable rectal cancer between February 1995 and Decem-
ber 2005 were enrolled retrospectively. Oncologic outcomes included 5-year cancer-specific survival and its affecting fac-
tors, as well as risk factors for local and systemic recurrence. 
Results: The 5-year cancer-specific survival rate was 77.53% with a mean follow-up period of 61 ± 31 months. The overall 
local and systemic recurrence rates were 9.2% and 21.1%, respectively. The risk factors for local recurrence were pN stage 
(P = 0.015), positive distal resection margin, and positive circumferential resection margin (P < 0.001). The risk factors for 
systemic recurrence were pN stage (P < 0.001) and preoperative carcinoembryonic antigen level (P = 0.005). The prognostic 
factors for cancer-specific survival were pT stage (P < 0.001), pN stage (P < 0.001), positive distal resection margin (P = 
0.005), and positive circumferential resection margin (P = 0.016). 
Conclusion: The oncologic outcomes in our institution after a TSME for patients with resectable rectal cancer were similar 
to those reported in other recent studies, and we established the risk factors that could be crucial for the planning of treat-
ment and follow-up.
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recurrence rate, deep pelvic location, and need for more compli-
cated adjuvant chemoradiotherapy (NCRT). Furthermore, surgi-
cal treatment combined with chemoradiotherapy is associated with 
many problems, such as permanent colostomy and urinary and 
sexual dysfunction, which reduce patients’ quality of life. There-
fore, careful consideration is required before starting treatment for 
rectal cancer. The local recurrence rate, which has been a major 
problem in the surgical treatment of rectal cancer, was as high as 
24% in research conducted by the German Rectal Cancer Study 
Group and the Gastrointestinal Tumor Study Group (GITSG) [1, 2]. 
However, the addition of chemoradiotherapy to surgical treatment 
reduced the local recurrence rates to 11% in the GITSG and 16% 
in the National Surgical Adjuvant Breast and Bowel Project (NSABP) 
R-01 studies [3, 4]. In 1990, the National Cancer Institute Consen-
sus Conference in the USA recommended chemoradiotherapy 
after the surgical resection of stage II/III rectal cancer [5].  
INTRODUCTION
The treatment of rectal cancer is made difficult by its higher local 
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In surgical technique, there has also been a remarkable effort to 
decrease the local recurrence of rectal cancer. The total mesorectal 
excision (TME) was introduced by Heald and Ryall [6] in 1982 
and dramatically reduced the local recurrence rate [7]. The TME 
has been a standard surgical technique for rectal cancer, but it has 
been used to treat all levels of rectal cancer so that the anastomotic 
leakage rate is high. As a result, the tumor-specific mesorectal ex-
cision (TSME) technique was introduced to achieve good local 
control and low morbidity. In the TSME, the conventional TME 
technique is applied to middle and distal rectal cancer, and a par-
tial mesorectal excision is applied, with sharp dissection through 
the mesorectal fascia 4 to 5 cm below the lower border of tumor, 
to proximal rectal cancer [8-10]. The TSME seems to be a more 
reasonable technique to reduce the complications caused by anas-
tomotic ischemia, and it has become widespread and is accepted 
as a standard surgical method for the treatment of rectal cancer. 
An optimal treatment modality for rectal cancer should be de-
veloped to decrease morbidity and mortality, as well as to increase 
the survival. The present study analyzed the oncologic outcomes 
and the prognostic factors after a TSME for stage I to III rectal can-
cer in order to provide information and evidence for planning the 
treatment modality of rectal cancer. 
METHODS
Patients
Between January 1995 and December 2005, 1,017 patients with 
primary rectal cancer underwent surgical resection in the Depart-
ment of Surgery, Busan Paik Hospital, Inje University College of 
Medicine. All patients who had a surgical resection for rectal can-
cer were registered in a prospectively collected colorectal cancer 
database and followed up. Seven hundred eighty-two patients with 
pathologic stage I to III tumors after the TSME were included in 
this study. Patients with distant metastasis, palliative resection, or no 
information about preoperative serum carcinoembryonic antigen 
(CEA) level or the distance from the anal verge (AV) were excluded. 
Rectal cancer was defined by sigmoidoscopy as a tumor with a 
lower border within 15 cm of the AV, and histopathologically con-
firmed adenocarcinoma with invasion of the submucosal layer. 
Rectal cancer was classified into three groups by its distance 
from the AV: distal (<7 cm from AV), mid (7 cm ≤ level < 12 cm 
from AV), and proximal (12 cm ≤ level ≤ 15 cm from AV). The 
survival rate was analyzed using data from the national cancer 
registry. All patients underwent surgical resection with a laparot-
omy because laparoscopic surgery has been used for patients with 
rectal cancer since 2006 at our institution. Anastomotic leakage 
was defined as definite disruption of anastomosis with high fever, 
abdominal pain, fecal material drainage, and leukocytosis that   
required surgical intervention such as a diverting enterostomy. 
Circumferential resection margin involvement was defined as a 
distance of < 1 mm between the outer margin and the mesorectal 
fascia.
Surgical therapy
Surgical resection was carried out after preoperative staging by 
digital rectal examination, rigid sigmoidoscopy, chest X-ray, tran-
srectal ultrasonography (TRUS), and abdominopelvic computed 
tomography (CT). A low midline incision that extended above 
the umbilicus was made. The inferior mesenteric artery was dou-
bly ligated at its origin, while carefully preserving the hypogastric 
nerve plexus. The inferior mesenteric vein was ligated at the same 
level as the inferior mesenteric artery. A sharp pelvic dissection was 
performed from the entrance to the pelvic cavity down to the pel-
vic floor, while preserving both the hypogastric nerve fibers and 
the pelvic nerve. Sharp pelvic dissections of the posterior and the 
anterior rectum were performed first, followed by a lateral dissec-
tion. Especially in male patients, a more careful dissection around 
the seminal vesicles was performed to avoid damage to the neuro-
vascular bundle. Dissection of the lateral side of the rectum was 
done with ligation of the midrectal artery and careful preservation 
of the pelvic nerve plexus. The mesorectum was cleared completely 
for middle and distal rectal cancers (<12 cm from AV) and was 
transected at 4 to 5 cm below the lower tumor margin for proxi-
mal rectal cancer (12 to 15 cm from AV). An ultra-low anterior 
resection was performed with straight coloanal anastomosis. A 
diverting enterostomy was performed only when the security of 
the anastomosis was uncertain, such as in cases of poor blood sup-
ply, poor bowel preparation, increased anastomotic tension, or 
positive air leak. An abdominoperineal resection (APR) was per-
formed by using a frozen sectional biopsy during an ultra-low an-
terior resection when anal sphincter invasion was identified dur-
ing preoperative evaluation and the distal resection margin was 
positive for a tumor. In the case of rectal cancer with obstruction 
or perforation, a TME or a TSME followed by Hartmann’s colos-
tomy was performed.
Adjuvant therapy
Adjuvant therapy was not routinely given to patients with patho-
logic stage II or III rectal cancer. Postoperative chemoradiother-
apy was given to those who had middle or distal rectal cancer only 
when local surgical control was in doubt, such as in cases of tu-
mor invasion of multiple lymph nodes, lymphovascular invasion, 
or a suspected positive resection margin. Postoperative chemo-
therapy was given to those who had proximal rectal cancer with 
the above risk factors. Chemotherapy was comprised of 425-mg/m
2 
5-fluorouracil for 5 days and 20-mg/m
2 leucovorin for 5 days in-
travenously, monthly for six cycles. Radiotherapy was started with 
a total of 5,040 cGy external beam radiation in 28 fractions at the 
beginning of the second cycle of chemotherapy. For proximal rec-
tal cancer, chemotherapy was given only to patients with positive 
lymph nodes. No adjuvant chemoradiotherapy was administered 
to patients who refused radiotherapy, were older than 75 years of 
age, or showed poor performance status. Preoperative chemora-
diotherapy was administered only when patients with T3 or T4 
stage tumors had bulky and fixed middle or distal rectal cancer, as Journal of The Korean Society of
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detected by digital rectal examination or sigmoidoscopy.
Follow-up
Patients were followed up every 3 months for the first 2 years after 
surgery and every 6 months thereafter for 3 years, for a total of         
5 years. History, physical examination, and serum CEA level were 
determined at each follow-up visit. Chest X-ray and abdomino-
pelvic CT were done at 6-month intervals, and colonoscopy was 
performed annually. Recurrence was identified by imaging stud-
ies and colonoscopy and was confirmed by colonoscopic or per-
cutaneous biopsy. When histologic confirmation was not possible, 
radiologically-observed tumor growth within the previous surgi-
cal field was considered to indicate recurrence.
Statistical analysis
Statistical analyses were performed using SAS ver. 9.2 (SAS Insti-
tute Inc., Cary, NC, USA). The χ2 test was used to analyze categor-
ical variables, and the student’s t-test was used for continuous vari-
ables. Survival was analyzed using the Kaplan-Meier method. The 
prognostic factors for survival and recurrence were analyzed with 
the log-rank test. Multivariate analyses were performed with the 
Cox proportional hazard model. P-values of less than 0.05 were 
considered statistically significant. 
RESULTS
Clinical and pathologic characteristics
Of the 782 patients, 421 (53.84%) were male, and 361 (46.16%) 
were female. The median age was 58.78 years (range, 27 to 96 years). 
The median distance of the tumor from the AV was 7.3 cm (range, 
1 to 15 cm). For the surgical procedure, 217 patients (27.75%) un-
derwent an APR, 526 (67.26%) a low anterior resection, 13 (1.66%) 
an ultra-low anterior resection, and 24 (3.07%) Hartmann’s opera-
Table 1. Clinical characteristics 
Characteristic No. (%)
Sex
   Male   421 (53.84)
   Female   361 (46.16)
Age (yr)
   Mean (SD) (range) 58.78 (11.34) (27-96)
   ≤59 355 (45.40)
   ≥60   427 (54.60)
Distance from AV (cm)
   Mean (SD) (range) 7.3 (3.36) (1-15)
Serum CEA level (ng/mL)
   Preoperative mean (SD) (range) 11.22 (33.85) (0.10-624)
   ≤5   552 (70.59)
   >5   230 (29.41)
Tumor size (cm)
    Mean (SD) (range)  4.83 (2.03) (0.5-13)
Operation type
   APR   217 (27.75)
   LAR   526 (67.26)
   uLAR   13 (1.66)
   Hartmann   24 (3.07)
   Other     2 (0.26)
Diverting colostomy   77 (9.93)
Anastomotic leakage   14 (1.79)
Adjuvant treatment
   Preoperative CRT   31 (3.96)
   Postoperative CRT   177 (22.63)
   Postoperative CTx   90 (11.5)
AV, anal verge; CEA, carcinoembryonic antigen; APR, abdominoperineal resection; 
LAR, low anterior resection; uLAR, ultra-low anterior resection; CRT, chemoradio-
therapy; CTx, chemotherapy.
Table 2. Histopathologic characteristics
Characteristic No. (%)
Histologic differentiation 
   Well 127 (16.24)
   Moderate 603 (77.10)
   Poor 16 (2.05)
   Mucinous 35 (4.48)
   Signet ring cell   1 (0.13)
Lymphovascular invasion
   Positive 287 (36.70)
Circumferential resection margin
   Involved 51 (6.52)
Distal margin (cm)
   Mean (SD) (range) 2.19 (1.83) (0.1-13)
Distal resection margin
   Involved   7 (0.90)
AJCC stage 
   I 177 (22.63)
   IIA 247 (31.59)
   IIB   6 (0.77)
   IIIA 25 (3.20)
   IIIB 166 (21.23)
   IIIC 161 (20.59)
   Stage I 177 (22.63)
   Stage II 253 (32.35)
   Stage III 352 (45.01)
AJCC, American Joint Committee on Cancer.Journal of The Korean Society of
Coloproctology
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tion. Anastomotic leakage after surgery was seen in 14 patients 
(1.79%). Preoperative chemoradiotherapy was performed in 31 
patients (3.96%) and postoperative chemoradiotherapy in 177 pa-
tients (22.63%); 90 patients (11.5%) were treated only with post-
operative chemotherapy (Table 1). The mean follow-up period was 
61 ± 31 months, and follow-up loss was 193 (24.9%). 
Histopathologic characteristics are shown in Table 2. Adenocar-
cinomas were well-differentiated in 127 patients (16.24%), mod-
erately differentiated in 603 (77.10%), poorly differentiated in 16 
(2.05%), mucinous in 35 (4.48%), and signet ring cell in one (0.13%). 
On histopathologic examination, vascular or lymphatic invasion 
was positive in 287 patients (36.7%); 7 patients (0.9%) showed dis-
tal resection margin involvement, and 51 (6.52%) showed circum-
ferential resection margin involvement. The American Joint Com-
mittee on Cancer (AJCC) system was used for staging, yielding the 
final pathologic tumor stages: stage I, 177 patients (22.63%); stage 
II, 253 patients (32.35%); and stage III, 352 patients (45.01%). 
Analysis of local and systemic recurrence
Local recurrence occurred in 72 patients (9.21%), with 30 cases 
(3.84%) in a previous anastomotic site, 23 cases (2.94%) in the 
pelvic cavity, and 14 cases (1.79%) in the presacral area (Table 3). 
Five-year local recurrence rates according to stage were 1.7% in 
stage I, 5.0% in stage II, and 10.8% in stage III (P = 0.002) (Fig. 1). 
In the univariate analysis, the risk factors for local recurrence were 
age (P = 0.046), pT stage (P = 0.018), pN stage (P < 0.001), lym-
phovascular invasion (P = 0.006), positive distal resection margin 
(P < 0.001), and positive circumferential resection margin (P < 
0.001) (Table 4). However, the multivariate analysis found that pN 
stage (P = 0.015), positive distal resection margin (P < 0.001), and 
positive circumferential resection margin (P < 0.001) were inde-
pendent risk factors for local recurrence (Table 4). Systemic recur-
rence occurred in 165 patients (21.1%), including 62 cases (7.93%) 
of lung metastasis, 45 cases (5.75%) of liver metastasis, and 24 cases 
(3.07%) of bone metastasis (Table 3). Five-year systemic recurrence 
rates according to AJCC stage were 0% in stage I, 13% in stage II, 
and 33.7% in stage III. Recurrence increased significantly with in-
creasing stage (Fig. 2). In the univariate analysis, the risk factors 
for systemic recurrence were pT stage (P < 0.001), pN stage (P < 
0.001), elevated preoperative serum CEA level (P < 0.001), histo-
logic grade (P = 0.049), lymphovascular invasion (P < 0.001), and 
positive circumferential resection margin (P = 0.0112) (Table 4). 
In the multivariate analysis, pN stage (P < 0.001) and preoperative 
serum CEA level (P = 0.006) were independent risk factors for 
systemic recurrence (Table 4).
Analysis of survival rates and prognostic factors
The 5-year cancer-specific survival rate was 77.53% and decreased 
significantly with increasing stage: 97.7% in stage I; 83% in stage II; 
and 61.33% in stage III (Fig. 3). In the univariate analysis, the risk 
factors for the 5-year cancer-specific survival rate were pT stage (P < 
0.001), pN stage (P < 0.001), preoperative serum CEA level (P = 
0.003), lymphovascular invasion (P < 0.001), positive distal resec-
tion margin (P < 0.001), and positive circumferential resection 
margin (P < 0.001) (Table 4). In the multivariate analysis, pT stage 
(P < 0.001), pN stage (P < 0.001), positive distal resection margin 
(P < 0.001), and positive circumferential resection margin (P = 
0.016) were independent risk factors for the 5-year cancer-specific 
survival rate (Table 4).
Table 3. Patterns of recurrence
Site  No. (%)
Local recurrence
   Anastomotic 30 (3.84)
   Pelvic 23 (2.94)
   Presacral 14 (1.79)
   Bladder   3 (0.38)
   Perineal   2 (0.26)
   Total 72 (9.21)
Systemic recurrence
   Lung 62 (7.93)
   Liver 45 (5.75)
   Bone 24 (3.07)
   Paraaortic lymph node   9 (1.15)
   Peritoneal seeding   8 (1.02)
   Inguinal lymph node   4 (0.51)
   Brain   3 (0.38)
   Others 10 (1.28)
   Total 165 (21.10)
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Fig. 1. Local recurrence rates according to pathologic tumor stage.
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Table 4. Analysis of prognostic factors 
Factor
Local recurrence Systemic recurrence Cancer-specific survival
5-Year
a Uni- 
variate
b
Multi- 
variate
C 5-Year
a Uni- 
variate
b
Multi- 
variate
C 5-Year
a Uni- 
variate
b
Multi- 
variate
C
Sex
   Male 7.12 0.529 19.92 0.594 75.89 0.281
   Female 5.60 17.90 79.40
Age (yr)
   <59 3.75 0.046 0.104 20.84 0.329 76.22 0.522
   >60 8.32 16.96 78.93
pT
   pT1 0 0.018 0.092 0 <0.001 0.103 98.41 <0.001 <0.001
   pT2 2.95 4.27 93.83
   pT3 7.30 24.76 70.51
   pT4 35.0 45.5 20.22
pN
   pN0 3.67 <0.001 0.015   7.53 <0.001 <0.001 89.65 <0.001 <0.001
   pN1 6.43 24.26 72.42
   pN2 17.87 45.01 49.71
Preoperative CEA (ng/mL)
   ≤5 6.60 0.646 15.37 <0.001 0.005 80.05 0.003 0.103
   >5 6.58 28.04 69.87
Histologic type
   Well differentiated 5.09 0.680 8.09 0.049 0.438 84.14 0.084 0.498
   Moderately differentiated 6.66 21.02 77.57
   Poorly differentiated 12.60 26.87 73.13
   Mucinous 12.74 21.37 62.22
   Sig-net ring cell 0 0 100
Distance from anal verge
   ≤6 8.31 0.314 17.63 0.655 75.80 0.595
   7-12 5.11 19.93 76.33
   ≥13 5.50 20.97 82.48
Lymphovascular invasion 0.006 0.106 <0.001 0.843 <0.001 0.598
   (-) 4.18 14.71 82.46
   (+) 10.87 26.70 68.57
Distal resection margin
   0 6.19 <0.001 <0.001 19.06 0.425 77.18 <0.001 <0.001
   1 31.43 0 42.86
Circumferential resection margin
   0 5.21 <0.001 <0.001 18.10 0.009 0.348 78.81 <0.001 0.016
   1 26.47 32.73 49.09
Anastomo-tic leakage
   0 6.36 0.479 18.96 0.750 76.79 0.966
   1 11.11 21.25 80.00
CEA, carcinoembryonic antigen.
a5-Year recurrence rate; 
bUnivariate analysis (P-value); 
cMultivariate analysis (P-value).Journal of The Korean Society of
Coloproctology
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DISCUSSION
The ideal treatment for rectal cancer should maximize sphincter 
preservation and lead to optimal oncologic outcomes character-
ized by low morbidity and mortality. In this study, the oncologic 
outcomes after a TSME of rectal cancer showed a 77.5% 5-year 
cancer-specific survival rate, a 9.2% local recurrence rate, and a 
21.1% systemic recurrence rate.
For the past 20 years, the results of treatment for rectal cancer 
have improved in terms of local recurrence and cancer-specific 
survival rates due to adjuvant chemoradiotherapy and optimized 
surgical techniques. The TME has reduced the local recurrence 
rate from 20 to 30% [1, 2] to 5 to 7% [11, 12]. Adjuvant chemora-
diotherapy after a curative resection of rectal cancer reduced the 
local recurrence rate from 24 to 11% in the GITSG study and from 
25 to 16% in the NSABP R-01 study [3, 4]. In 1990, these two ran-
domized trials prompted a National Cancer Institute Consensus 
Conference in the USA to recommend postoperative adjuvant 
chemoradiotherapy for patients with T3-stage rectal cancer, in-
volvement of lymph nodes, or both [5]. However, efforts to opti-
mize the surgical technique led to the TME being changed to the 
TSME because the TME had a high morbidity associated with an 
anastomotic leakage rate of 23.5% [7-10, 13]. In the TSME, a TME 
is performed for middle and distal rectal cancer, and a partial me-
sorectal excision with sharp pelvic dissection is performed for prox-
imal rectal cancer. The TSME has been associated with a local re-
currence rate of 9.2% at our institution, which is comparable to 
another TSME study, with a rate of 9.7%, reported by Law and 
Chu [13], but unfavorable compared with the 5.4% rate reported 
by Kim et al. [14]. This difference seems to be due to the applica-
tion of adjuvant chemoradiotherapy, which was performed in all 
patients with postoperative pathologic stages exceeding II in the 
study of Kim et al. [14], but was not routinely performed for pa-
tients in the study of Law and Chu [13]; in the latter series, adju-
vant chemoradiotherapy was performed only when local clearance 
was in doubt. In the present study, we did not perform adjuvant 
chemoradiotherapy in any patient with a tumor stage exceeding 
stage II; rather, we used it almost postoperatively in selective pa-
tients with multiple lymph-node invasion, lymphovascular inva-
sion, or suspected positive resection margins. Thus, the slightly 
high rate of local recurrence seemed to be caused by not routinely 
administering adjuvant chemoradiotherapy after the TSME. There-
fore, the use of adjuvant chemoradiotherapy in all patients with 
tumor stages exceeding stage II would be helpful to improve the 
local recurrence rate after a TSME. In 2004, the German Rectal 
Cancer Trial [15] compared the applications of preoperative and 
postoperative chemoradiotherapy, and reported a 13% 5-year local 
recurrence rate after postoperative treatment and a 6% rate after 
preoperative treatment. Thus, in 2009, the National Comprehen-
sive Cancer Network guidelines designated preoperative chemo-
radiotherapy as a standard therapy in clinical stage II/III patients 
with suspected lymph-node invasion and cT3 stage [16]. In the 
present study, we found that pN stage, positive distal resection mar-
gin, and positive circumferential resection margin were indepen-
dent risk factors for local recurrence. These factors are similar to 
those of other TME studies [13, 17-19], so if these risk factors are 
predicted in the preoperative magnetic resonance image or TRUS, 
more aggressive NCRT should be performed with the TSME. How-
ever, for effective use of NCRT, more accurate diagnostic tools are 
needed for predicting risk factors, which include positive lymph 
nodes, circumferential resection involvement, and anal sphincter 
involvement, because a patient with a lower stage than expected 
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Fig. 2. Systemic recurrence rates according to pathologic tumor stage. 
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Fig. 3. Cancer-specific survival rates according to pathologic tumor stage.
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or with no risk factors could be over-treated. Also, predictive fac-
tors for response to NCRT should be developed because patients 
with disease during NCRT would be treated by using a useless 
method. Kim et al. [14] suggested that preoperative chemoradio-
therapy would be better in patients with rectal cancer localized in 
the distal rectum and in high-risk patients such as those with a 
positive circumferential resection margin and invasion of the anal 
sphincter. Until more accurate diagnostic tools and predictive fac-
tors for response to NCRT are developed, the suggestion of Kim 
et al. [14] could provide good selective indications for effective 
use of NCRT. 
The rates of systemic recurrence have been reported to be 16.3 to 
22.1%, which are similar to our present results [14, 20-22]. Known 
risk factors for systemic recurrence include sex, tumor stage, cir-
cumferential resection margin, and preoperative serum CEA level 
[14, 17, 22]. In the present study, the multivariate analysis revealed 
that the risk factors for systemic recurrence were pN stage and pre-
operative serum CEA level. Systemic adjuvant chemotherapy should 
also be considered when these factors are detected, and more effec-
tive regimens, such as the adjuvant chemotherapeutic regimens 
for colon cancer should be tried.
Our analysis of 782 cases of rectal cancer with pathologic stage I 
to III cancer after a TSME found a 5-year cancer-specific survival 
rate of 77.5%, a local recurrence rate of 9.2%, and a systemic recur-
rence rate of 21.1%. The risk factors affecting the cancer-specific 
survival rate were pT stage, pN stage, positive distal resection mar-
gin, and positive circumferential resection margin. The risk factors 
affecting local recurrence were pN stage, positive distal resection 
margin, and positive circumferential resection margin. The risk 
factors affecting systemic recurrence were pN stage and preopera-
tive CEA level. 
In conclusion, the oncologic outcomes at our institution after a 
TSME for patients with resectable rectal cancer were similar to 
those reported in other recent studies, and we established the risk 
factors that could be crucial for the planning of treatment and fol-
low-up.
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